Meiragtx Holdings ((MGTX)) announced an update on their ongoing clinical study.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
MeiraGTx Holdings is conducting a clinical study titled ‘A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia.’ The study aims to evaluate the effectiveness and safety of the AAV2-hAQP1 gene therapy in adults suffering from late-stage xerostomia caused by radiation therapy, a condition that significantly impacts quality of life.
The intervention being tested is a genetic therapy called AAV2-hAQP1, administered directly into the parotid glands. This therapy is designed to alleviate symptoms of xerostomia by potentially restoring salivary function.
The study follows a randomized, parallel intervention model with triple masking (participant, investigator, outcomes assessor) to ensure unbiased results. The primary purpose of the study is treatment-focused, aiming to provide a new therapeutic option for affected individuals.
The study began on June 22, 2023, and is currently recruiting participants. The last update was submitted on August 19, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
The outcome of this study could significantly influence MeiraGTx’s stock performance, as successful results may lead to increased investor confidence and market interest. In the competitive landscape of gene therapy, this study positions MeiraGTx as a potential leader in addressing radiation-induced xerostomia.
The study is ongoing, with further details available on the ClinicalTrials portal.